Cipla Ltd, established in 1935, is a prominent Indian pharmaceutical company engaged in manufacturing, developing, and marketing a diverse range of branded and generic formulations, as well as Active Pharmaceutical Ingredients (APIs). Its comprehensive product portfolio covers therapeutic areas such as respiratory, anti-retroviral, urology, cardiology, and anti-infective drugs. Cipla has a significant global presence, with 47 manufacturing sites worldwide, producing over 1,500 products in more than 50 dosage forms.
The company has expanded its reach into key markets including India, South Africa, North America, and other regulated and emerging regions. Cipla has a history of strategic collaborations and acquisitions, such as its acquisition of South Africa's Cipla Medpro and its investment in various biotechnology firms. Recently, Cipla has focused on digital health and innovation, introducing advanced diagnostic devices and expanding its specialty product portfolio. The company continues to diversify its offerings through investments in renewable energy and biosimilars, enhancing its global footprint and capabilities.
